Asahi Kasei Pharma Corp. remains entitled to more than $520 million in damages after the California Supreme Court March 12 unanimously denied review of a jury verdict that Actelion Ltd. interfered with Asahi’s development of a competing pulmonary arterial hypertension drug (Asahi Kasei Pharm. v. Actelion Ltd.).
The decision keeps in place what Asahi’s attorneys at Morgan Lewis LLP estimated will be a final judgment of $523 million against Actelion. Asahi, which is based in Japan, had alleged that Actelion competitively and tortiously interfered with Asahi’s license agreement with CoTherix Inc. to develop a PAH treatment by buying ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.